- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
ANDA Approvals
2011/2012
Approval Date | Reference Listed Drug | Generic Drug Name | NDA Holder | ANDA Applicant |
---|---|---|---|---|
10/3/2011 | Propecia | Finasteride | Merck | Sun Pharma Global |
10/3/2011 | Unipen | Nafcillin Sodium | Wyeth | Acic Fine Chems |
10/4/2011 | Keppra XR | Levetiracetam | Ucb Inc | Anchen Pharms |
10/06/2011 | Lamictal | Lamotrigine | Glaxosmithkline | Unichem Labs Ltd |
10/06/2011 | Leustatin | Cladribine | Janssen Pharms | Onco Therapies Ltd |
10/06/2011 | Neurontin | Gabapentin | Pfizer Pharms | Aurobindo Pharma Ltd |
10/07/2011 | Retrovir | Zidovudine | Viiv Hlthcare | Hec Pharm Inc |
10/13/2011 | Keppra XR | Levetiracetam | Ucb Inc | Hikma Farmaceutica |
10/17/2011 | Keppra XR | Levetiracetam | Ucb Inc | Lupin Ltd |
10/17/2011 | Derma-Smoothe/FS | Fluocinolone Acetonide | Hill Dermac | Identi Pharms Inc |
10/17/2011 | Derma-Smoothe/FS | Fluocinolone Acetonide | Hill Dermac | Identi Pharms Inc |
10/17/2011 | Derma-Smoothe/FS | Fluocinolone Acetonide | Hill Dermac | Identi Pharms Inc |
10/18/2011 | Marcaine Hydrochloride | Bupivacaine Hydrochloride | Hospira | Sagent Strides |
10/18/2011 | Marcaine Hydrochloride | Bupivacaine Hydrochloride | Hospira | Sagent Strides |
10/18/2011 | Marcaine Hydrochloride | Bupivacaine Hydrochloride | Hospira | Sagent Strides |
10/18/2011 | MS Contin | Morphine Sulfate | Purdue Pharma LP | Mylan Pharms Inc |
10/19/2011 | Robinul | Glycopyrrolate | Shionogi Inc | Boca Pharma |
10/19/2011 | Zinecard | Dexrazoxane Hydrochloride | Pharmacia And Upjohn | Mylan Institutional |
10/21/2011 | Robaxin | Methocarbamol | Schwarz Pharma | Austarpharma Llc |
10/24/2011 | Zyprexa | Olanzapine | Lilly | Teva Pharms |
10/24/2011 | Zyprexa | Olanzapine | Lilly | Dr Reddys Labs Ltd |
10/24/2011 | Zyprexa | Olanzapine | Lilly | Par Pharm |
10/24/2011 | Zyprexa | Olanzapine | Lilly | Apotex Inc |
10/24/2011 | Zyprexa | Olanzapine | Lilly | Innopharma Llc |
10/24/2011 | Tenuate Dospan | Diethylpropion Hydrochloride | Watson Pharms | Lannett Holdings Inc |
10/25/2011 | Adderall | Dextroamphetamine Sulfate | Teva And Barr Pharmaceuticals | Mikart |
10/25/2011 | Zyprexa | Olanzapine | Lilly | Torrent Pharms Llc |
10/25/2011 | Loseasonique (Generic Drug) | Ethinyl Estradiol; Levonorgestrel | Teva Womens | Watson Labs |
10/26/2011 | Cefotetan | Cefotetan Disodium | App Pharms | West-Ward Pharm Corp |
10/26/2011 | Cefotetan | Cefotetan Disodium | App Pharms | West-Ward Pharm Corp |
10/26/2011 | Merrem | Meropenem | Astrazeneca | Acs Dobfar |
10/26/2011 | Loseasonique (Generic Drug) | Ethinyl Estradiol; Levonorgestrel | Teva Womens | Lupin Ltd |
10/27/2011 | Cellcept | Mycophenolate Mofetil | Allergan | Dr Reddys Labs Ltd |
10/27/2011 | Gastrocrom | Cromolyn Sodium | Azur Pharma | Pack Pharms Llc |
10/28/2011 | Cardizem CD | Diltiazem Hydrochloride | Valeant Intl | Sun Pharma Global |
10/28/2011 | Doxil | Doxorubicin Hydrochloride | Janssen Pharms | Onco Therapies Ltd |
10/31/2011 | Elestat | Epinastine Hydrochloride | Allergan | Apotex |
10/31/2011 | Elestat | Epinastine Hydrochloride | Allergan | Pharmaforce |
10/31/2011 | Elestat | Epinastine Hydrochloride | Allergan | Sun Pharm Inds |
10/31/2011 | Anaprox | Aurobindo Pharma Ltd | Allergan | Aurobindo Pharma Ltd |
11/03/2011 | Cyklokapron | Tranexamic Acid | Pharmacia And Upjohn | Bioniche Pharma |
11/04/2011 | Plendil | Felodipine | Astrazeneca | Endo Pharms |
11/04/2011 | Gabitril | Tiagabine Hydrochloride | Tiagabine Hydrochloride | Sun Pharm Inds |
11/04/2011 | Risperdal | Risperidone | Janssen Pharms | Jubilant Organosys |
11/04/2011 | Cellcept | Mycophenolate Mofetil | Roche Palo | Alkem Labs Ltd |
11/07/2011 | XyzalL | Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | Synthon Pharms |
11/08/2011 | Naprosyn | Naproxen | Roche Palo | Aurobindo Pharma Usa |
11/09/2011 | Carboplatin | Carboplatin | Teva Parenteral / Pharmachemie | Onco Therapies Ltd |
11/10/2011 | Tylenol With Codein | Acetaminophen; Codeine Phosphate | Ortho-McNeil Pharma | Vintage Pharms |
11/10/2011 | Kadian | Morphine Sulfate | Actavis Elizabeth | Watson Labs |
11/16/2011 | Primaxin | Cilastatin Sodium; Imipenem | Merck | Hospira Inc |
11/16/2011 | Primaxin | Cilastatin Sodium; Imipenem | Merck | Hospira Inc |
11/16/2011 | Teveten | Eprosartan Mesylate | Abbott | Mylan Pharms Inc |
11/17/2011 | Epivir | Lamivudine | Viiv Hlthcare | Aurobindo Pharma Ltd |
11/17/2011 | Cyklokapron | Tranexamic Acid | Pharmacia And Upjohn | Versapharm Inc |
11/18/2011 | Buphenyl | Sodium Phenylbutyrate | Medicis | Ampolgen |
11/21/2011 | Arava | Leflunomide | Sanofi Aventis US | Alembic Pharms Ltd |
11/23/2011 | Loseasonique (Generic Drug) | Ethinyl Estradiol; Levonorgestrel | Teva Womens | Vintage Pharms |
11/23/2011 | Carboplatin | Carboplatin | Teva Parenteral / Pharmachemie | Onco Therapies Ltd |
11/25/2011 | Carbatrol | Carbamazepine | Shire | Apotex Inc |
11/28/2011 | Lovenox | Enoxaparin Sodium | Sanofi Aventis US | Sandoz Inc |
11/28/2011 | Yaz | Drospirenone; Ethinyl Estradiol | Bayer Hlthcare | Watson Labs |
11/28/2011 | Ultram | Tramadol Hydrochloride | Janssen Pharms | Alvogen |
11/28/2011 | Plendil | Felodipine | Astrazeneca | Torrent Pharms Ltd |
11/29/2011 | Risperdal | Risperidone | Janssen Pharms | Prinston Inc |
11/30/2011 | Lipitor | Atorvastatin Calcium | Pfizer | Ranbaxy Labs Ltd |
11/30/2011 | Solodyn | Minocycline Hydrochloride | Medicis | Lupin Ltd |
12/01/2011 | Ritalin LA | Methylphenidate Hydrochloride | Novartis | Actavis |
12/02/2011 | Epivir | Lamivudine | Viiv Hlthcare | Apotex |
12/06/2011 | Pamine | Methscopolamine Bromide | Nycomed US | Breckenridge Pharm |
12/06/2011 | Catapres | Clonidine Hydrochloride | Boehringer Ingelheim | Alembic Pharms Ltd |
12/06/2011 | Sanctura | Trospium Chloride | Allergan | Apotex |
12/07/2011 | Glucophage | Metformin Hydrochloride | Bristol Myers Squibb | Apotex |
12/07/2011 | Ultram | Tramadol Hydrochloride | Valeant Intl | Sun Pharma Global |
12/09/2011 | Dyazide | Hydrochlorothiazide; Triameterene | Glaxosmithkline | Lannett Holdings Inc |
12/12/2011 | Vfend | Voriconazole | Pfizer | Sandoz Inc |
12/13/2011 | Ritalin LA | Methylphenidate Hydrochloride | Novartis | Actavis |
12/13/2011 | Cytarabine | Cytarabine | Hospira | Onco Therapies Ltd |
12/13/2011 | Cytarabine | Cytarabine | Hospira | Onco Therapies Ltd |
12/13/2011 | Cytarabine | Cytarabine | Hospira | Onco Therapies Ltd |
12/14/2011 | Doryx | Doxycycline Hyclate | Mayne Pharma | Actavis Elizabeth |
12/15/2011 | Toprol XL (Lopressor) | Metoprolol Succinate | Novartis | Mylan Pharms Inc |
12/16/2011 | Camptosar | Irinotecan Hydrochloride | Pfizer | Jiangsu Hengrui Med |
12/16/2011 | Felbamate | Felbamate | Meda Pharms | Amneal Pharms |
12/19/2011 | Keppra XR | Levetiracetam | UCB Inc | Mylan Pharms Inc |
12/20/2011 | Vibramycin | Doxycyline | Pfizer | Heritage Pharms Inc |
12/20/2011 | Augmentin / Clavamox | Amoxicillin; Clavulante Potassium | Glaxosmithkline / Pfizer | Aurobindo Pharma Ltd |
12/20/2011 | Augmentin / Clavamox | Amoxicillin; Clavulante Potassium | Glaxosmithkline / Pfizer | Aurobindo Pharma Ltd |
12/21/2011 | Kayexalate | Sodium Polystyrene Sulfonate | Sanofi Aventis US | Cedar Pharms |
12/21/2011 | Unasyn | Ampicillin Sodium; Sulbactam Sodiu | Pfizer | Hospira Inc |
12/21/2011 | Primaxin | Cilastatin Sodium; Imipenem | Merck | Acs Dobfar |
12/21/2011 | Unasyn | Ampicillin Sodium; Sulbactam Sodiu | Pfizer | Hospira Inc |
12/21/2011 | Unasyn | Ampicillin Sodium; Sulbactam Sodiu | Pfizer | Hospira Inc |
12/21/2011 | Fludara | Fludarabine Phosphate | Teva Parenteral / Sandoz | Onco Therapies Ltd |
12/22/2011 | Clarinex | Desloratadine | Schering Plough | Perrigo R and D |
12/22/2011 | Generess Fe | Norethindrone; Ethinyl Estradiol | Watson Pharms | Novast Labs Ltd |
12/22/2011 | Ortho-Novum 7/7/7-28 | Ethinyl Estradiol; Norethindrone | Janssen Pharms | Novast Labs Ltd |
12/22/2011 | Ovcon-35 | Ethinyl Estradiol; Norethindrone | Warner Chilcott | Novast Labs Ltd |
12/22/2011 | Ortho-Novum | Ethinyl Estradiol; Norethindrone | Janssen Pharms | Novast Labs Ltd |
12/23/2011 | Tricor | Fenofibrate | Abbott Labs Pharm | Lupin Ltd |
12/23/2011 | Urso Forte | Ursodiol | Aptalis Pharma US | Watson Labs Inc |
12/30/2011 | Osmoprep | Sodium Phosphate, Diabasic anhydrous; Sodium Phosphate, Monobasic, Monohydrate | Salix | Novel Labs Inc |
12/30/2011 | Relafen | Nabumetone | Smithkline Beecham | Apotex Inc |
12/30/2011 | Isoptin SR | Verapamil Hydrochloride | Pfizer | Sun Pharm Inds |
GENERICally Speaking Winter 2011/2012
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.